Abstract
The past decade has witnessed the introduction of a diverse group of antidepressants from a variety of distinct chemical classes, each with their own specificity for neurochemical transmitters, receptors, and cytochrome P450 isozymes. This review focuses on nefazodone, a distinct antidepressant with efficacy for the treatment of depression with depression-related anxiety symptoms, an established tolerability profile, and a multimodal mechanism of action. Relevant pharmacologic and pharmacodynamic effects are summarized that support nefazodone as an attractive choice for both the short- and long-term treatment of depression.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antidepressive Agents, Second-Generation / pharmacokinetics
-
Antidepressive Agents, Second-Generation / pharmacology*
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Anxiety Disorders / drug therapy
-
Depressive Disorder / drug therapy*
-
Drug Interactions
-
Humans
-
Piperazines
-
Receptors, Serotonin / drug effects
-
Selective Serotonin Reuptake Inhibitors / pharmacology
-
Serotonin Antagonists / pharmacokinetics
-
Serotonin Antagonists / pharmacology
-
Serotonin Antagonists / therapeutic use
-
Sleep / drug effects
-
Sleep / physiology
-
Triazoles / pharmacokinetics
-
Triazoles / pharmacology*
-
Triazoles / therapeutic use
Substances
-
Antidepressive Agents, Second-Generation
-
Piperazines
-
Receptors, Serotonin
-
Serotonin Antagonists
-
Serotonin Uptake Inhibitors
-
Triazoles
-
nefazodone